[go: up one dir, main page]

CL2021003312A1 - Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. - Google Patents

Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.

Info

Publication number
CL2021003312A1
CL2021003312A1 CL2021003312A CL2021003312A CL2021003312A1 CL 2021003312 A1 CL2021003312 A1 CL 2021003312A1 CL 2021003312 A CL2021003312 A CL 2021003312A CL 2021003312 A CL2021003312 A CL 2021003312A CL 2021003312 A1 CL2021003312 A1 CL 2021003312A1
Authority
CL
Chile
Prior art keywords
pridopidine
huntington
symptoms
disease
analog
Prior art date
Application number
CL2021003312A
Other languages
English (en)
Inventor
Michael Hayden
Michal Geva
Elena Berelovich
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/438,508 external-priority patent/US11090297B2/en
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of CL2021003312A1 publication Critical patent/CL2021003312A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a un método de tratamiento de un paciente humano afectado por la enfermedad de Huntington y/o síntomas de la misma, que comprende la administración al paciente de una composición farmacéutica que comprende pridopidina o una sal farmacéuticamente aceptable de la misma y un análogo de la misma o una sal farmacéuticamente aceptable de la misma.
CL2021003312A 2019-06-12 2021-12-10 Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. CL2021003312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/438,508 US11090297B2 (en) 2013-06-21 2019-06-12 Pridopidine for treating huntington's disease

Publications (1)

Publication Number Publication Date
CL2021003312A1 true CL2021003312A1 (es) 2022-08-26

Family

ID=73782137

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003312A CL2021003312A1 (es) 2019-06-12 2021-12-10 Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.

Country Status (12)

Country Link
EP (1) EP3982963A4 (es)
JP (2) JP7436524B2 (es)
CN (1) CN113950328A (es)
AU (1) AU2020293739B2 (es)
BR (1) BR112021024744A2 (es)
CA (1) CA3137633A1 (es)
CL (1) CL2021003312A1 (es)
EA (1) EA202193190A1 (es)
IL (1) IL288940A (es)
MX (1) MX2021015338A (es)
NZ (1) NZ782528A (es)
WO (1) WO2020250234A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232033A1 (en) * 2020-10-20 2023-08-30 Prilenia Neurotherapeutics Ltd. Use of pridopidine and analogs for the treatment of anxiety and depression
WO2025041080A1 (en) * 2023-08-22 2025-02-27 Philera New Zealand Ltd. Selenium deficiency analysis and treatments
CN118649245A (zh) * 2024-08-16 2024-09-17 北京市疾病预防控制中心 聚乙烯吡咯烷酮修饰的钯纳米颗粒在制备治疗亨廷顿舞蹈症的产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US9012476B2 (en) * 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
EA201590654A1 (ru) * 2012-09-27 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
HK1211525A1 (en) * 2012-09-27 2016-05-27 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
PL3010506T3 (pl) * 2013-06-21 2021-11-02 Prilenia Neurotherapeutics Ltd. Pridopidyna w leczeniu choroby huntingtona
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
FI3504187T3 (fi) * 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten

Also Published As

Publication number Publication date
MX2021015338A (es) 2022-01-18
IL288940A (en) 2022-02-01
EA202193190A1 (ru) 2022-03-24
JP2022535929A (ja) 2022-08-10
CA3137633A1 (en) 2020-12-17
AU2020293739B2 (en) 2023-11-30
JP7436524B2 (ja) 2024-02-21
EP3982963A1 (en) 2022-04-20
NZ782528A (en) 2025-05-02
EP3982963A4 (en) 2023-06-21
CN113950328A (zh) 2022-01-18
WO2020250234A1 (en) 2020-12-17
AU2020293739A1 (en) 2021-12-16
JP2024016113A (ja) 2024-02-06
BR112021024744A2 (pt) 2022-03-22

Similar Documents

Publication Publication Date Title
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BR112023021131A2 (pt) Tratamento de tremor essencial
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
AR119159A1 (es) Tratamientos de angioedema
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
BRPI0415215B8 (pt) uso de polifenol na preparação de medicamento
CL2022000781A1 (es) Tratamientos cognitivos medicinales
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CO2023006028A2 (es) Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
BR112018072164A2 (pt) composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição